Background: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) is inappropriate 1 . Objectives: To describe factors influencing the use of TCZ in Mono or in combination with DMARDs (Combo) in real-life practice in RA patients (pts). Methods: Analysis: pooled data of 3 prospective, multicentre, observational studies (PEPS n=610, Spare-1 n=307, Act-solo n=577 Conclusions: This pooled analysis suggests that physicians preferably prescribe TCZ alone in older patients, heavily treated before, with higher inflammatory markers and higher pain VAS. This use might be explained by physicians' reluctance to prescribe the association in frailer patients and complementary data on comorbidity factors will be analysed to support this hypothesis. Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, mononuclear cell infiltration, bone erosion and joint destruction. Antirheumatic treatment plays a important role in controlling the inflammation of rheumatoid arthritis and in minimizing joint damage. Rituximab -it is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells. It has been successfully used to treat rheumatoid arthritis, and it is worth noting that his antidestructive effect sometimes does not meet the clinical.
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Objectives: to assess clinical and antidestructive effect of Rituximab (RTX) in patients with rheumatoid arthritis (RA). Methods: 108 patients (pts) with RA, most of them were middle-age women with high disease activity (mean DAS28 6,1±1,04, RF-positive 77%, ACCP-positive 83%) treated with RTX (1000 mgx2 or 500 mgx2). Clinical effect was evaluated by EULAR criteria; radiological progression by SVH method. Results: 104 patients were treated by RTX (500 x2 or 1000 x2), had good response: after 48 week of treatment clinical improvement was achieved in 65% pts, good and moderate response by EULAR criteria in 23% and 42% pts accordingly. Noteworthy, after 12 months of treatment RTX radiological progression was absent in 50% pts with high disease activity. (26) or combined with other DMARDs (37); LFN (15), Cyclosporin (1), sulfasalazine (4), MTX (6), hydroxychloroquine (10), azathioprine (4), chloroquine (1). Table 1 shows the evolution in the available cases. A significant improvement in dyspnea and HRCT was observed in the NIU type. DLCO remained stable in most patients regardless of the radiological pattern. The activity of RA (DAS28) also improved. Table 1 Conclusions: ABA appears to be effective in ILD associated-RA, including the pattern of poor prognosis (UIP). Background: Bone and joint damage due to chronic inflammation in the synovium of patients with RA is mediated by IL-6 and other cytokines. IL-6 mediates effects inside the joint and systemically and is blocked by sarilumab, a human mAb blocking the IL-6R?. Safety and efficacy of SC sarilumab (150 or 200 mg q2w) was evaluated in combination with MTX in patients with RA and inadequate response (IR) to MTX (MOBILITY; NCT01061736) or csDMARDs in patients with RA and IR or intolerance to ≥1 TNFi (TARGET; NCT01709578). Objectives: To compare gene expression patterns in circulating blood cells after treatment with sarilumab vs placebo in patients from MOBILITY and TARGET. Methods: Total RNA was isolated from whole blood collected at baseline (predose) and wk 2 posttreatment in patients from MOBILITY (placebo, n=58; sarilumab 150 mg q2w, n=60; sarilumab 200 mg q2w, n=46) and TARGET (placebo, n=19; sarilumab 150 mg q2w, n=27; sarilumab 200 mg q2w, n=16). Gene expression data were generated using microarray analyses (Agilent 8 × 60k platform). Data were processed using the limma package (R Bioconductor). Background correction and quantile normalization were performed and probes with low expression were filtered; 48,109 probes were analyzed. Effect of sarilumab vs placebo on gene expression was assessed in each study using linear mixed models. P values were adjusted using the Benjamini-Hochberg procedure to control false discovery rate (FDR; 5% threshold). Results: After P value adjustment to control FDR at 5%, 2 genes implicated in thrombosis and atherosclerosis (thrombomodulin [THBD] and platelet endothelial cell adhesion molecule 1 [PECAM-1]) were downregulated after treatment with sarilumab 200 mg q2w vs placebo in both studies (Table) . These genes decreased with a fold-change (FC) ≤0.8 in both studies (P<0.001). An additional gene associated with coagulation, von Willebrand factor (vWF), was significantly decreased in MTX-IR but not TNF-IR patients. Numerical decreases in gene expression between sarilumab 150 mg q2w and placebo did not reach significance. 
Conclusions

Conclusions:
In patients with active RA, sarilumab may decrease thrombosisrelated gene expression in circulating immune cells. Additional analysis of the serum levels of thrombosis risk proteins is needed to test the hypothesis that sarilumab treatment decreases levels of thrombosis risk factors.
